Dermatomyositis

10
Pipeline Programs
8
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
6
0
4
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 9 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Corbus Pharmaceuticals
2 programs
1
1
Lenabasum 20 mgPhase 31 trial
JBT-101Phase 21 trial
Active Trials
NCT02466243Terminated22Est. Jan 2021
NCT03813160Completed176Est. Oct 2021
Octapharma
OctapharmaAustria - Vienna
2 programs
2
Octagam 10%Phase 31 trial
OctanormPhase 31 trial
Active Trials
NCT02728752Completed95Est. Nov 2019
NCT03686969Terminated1Est. Nov 2018
CSL Behring
CSL BehringIL - Bradley
1 program
1
human immunoglobulin GPhase 31 trial
Active Trials
NCT04044690Terminated134Est. Dec 2024
Pfizer
PfizerNEW YORK, NY
1 program
1
Anti-Beta InterferonPhase 21 trial
Active Trials
NCT05192200Completed24Est. Nov 2023
argenx
argenxBelgium - Zwijnaarde
1 program
1
Empasiprubart IVPhase 21 trial
Active Trials
NCT06284954Active Not Recruiting3Est. Nov 2026
Galapagos
Galapagos2800 MECHELEN, Belgium
1 program
1
GLPG3667Phase 21 trial
Active Trials
NCT05695950Active Not Recruiting40Est. Apr 2026
NovelMed Therapeutics
NovelMed TherapeuticsOH - Cleveland
1 program
1
NM8074Phase 21 trial
Active Trials
NCT06887738Not Yet RecruitingEst. Dec 2028
Genentech
GenentechCA - Oceanside
1 program
1
tocilizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT02043548Completed36Est. Jul 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
CSL Behringhuman immunoglobulin G
Corbus PharmaceuticalsLenabasum 20 mg
OctapharmaOctanorm
OctapharmaOctagam 10%
NovelMed TherapeuticsNM8074
argenxEmpasiprubart IV
GalapagosGLPG3667
PfizerAnti-Beta Interferon
Corbus PharmaceuticalsJBT-101
Genentechtocilizumab

Clinical Trials (10)

Total enrollment: 531 patients across 10 trials

NCT04044690CSL Behringhuman immunoglobulin G

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

Start: Oct 2019Est. completion: Dec 2024134 patients
Phase 3Terminated
NCT03813160Corbus PharmaceuticalsLenabasum 20 mg

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

Start: Dec 2018Est. completion: Oct 2021176 patients
Phase 3Completed
NCT03686969OctapharmaOctanorm

Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis

Start: Aug 2018Est. completion: Nov 20181 patients
Phase 3Terminated
NCT02728752OctapharmaOctagam 10%

Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)

Start: Feb 2017Est. completion: Nov 201995 patients
Phase 3Completed
NCT06887738NovelMed TherapeuticsNM8074

Study of NM8074 in Patients with Dermatomyositis (DM)

Start: Jun 2026Est. completion: Dec 2028
Phase 2Not Yet Recruiting
NCT06284954argenxEmpasiprubart IV

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Start: Aug 2024Est. completion: Nov 20263 patients
Phase 2Active Not Recruiting
NCT05695950GalapagosGLPG3667

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

Start: Feb 2023Est. completion: Apr 202640 patients
Phase 2Active Not Recruiting
NCT05192200PfizerAnti-Beta Interferon

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

Start: Dec 2021Est. completion: Nov 202324 patients
Phase 2Completed
NCT02466243Corbus PharmaceuticalsJBT-101

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Start: Jun 2015Est. completion: Jan 202122 patients
Phase 2Terminated
NCT02043548Genentechtocilizumab

Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

Start: Oct 2014Est. completion: Jul 201936 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
8 companies competing in this space